Implications of direct and indirect costs in health-related quality of life in Parkinson’s disease: A cross-sectional study in Mexico
Objective: To evaluate the association of direct and indirect costs of Parkinson's disease (PD) and health-related quality of life (HRQoL) in a Mexican population. Background:…Neuroprotection effect of an endogenous amine, 1MeTIQ against disturbances in dopamine release induced by the neurotoxin, 6-OHDA: In vivo microdialysis study
Objective: The aim of the present study was to investigated using microdialysis methodology the impact of 1MeTIQ on the disturbances of in vivo dopamine release…Progress in the development of small molecules based on the coumarin core as multifunctional neuroprotective agents
Objective: Taking into account the background of our research group and the knowledge that MAO and ChE activity generates ROS that cause neuronal cell death,…Drug safety in the pharmacotherapy of Parkinson’s disease
Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial
Objective: To compare hospitalisation rates of Parkinson's disease (PD) patients randomised between three different classes of oral medications used for early PD treatment. Background: PD…Randomised trial comparing dopamine agonist, MAOB inhibitor and COMT inhibitor as adjuvant therapy in later Parkinson’s disease (PD)
Objective: The PD MED trial aimed to determine which class of drug provides the best patient-rated quality of life (QoL) when used as adjuvant therapy…Extended-release carbidopa-levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson’s disease
Objective: Evaluate the efficacy and dosing of IPX066 in patient groups taking concomitant Parkinson's disease (PD) medication, using post hoc subgroup analyses. Background: IPX066 is…Rasagiline treatment for sleep disorders in Parkinson’s disease (RaSPar) – Double-blinded, randomized, placebo-controlled, placebo run-in-phase, polysomnography clinical trial
Objective: To study the effects of Rasagiline on sleep disturbances measured by polysomnographic (PSG) evaluation of sleep efficacy and secondary measures as other sleep variables,…Medication use patterns vary across expert Parkinson’s disease clinics
Objective: This analysis aims to describe and quantify the medication patterns for patients with Parkinson's disease (PD) managed in expert clinics. Background: Antiparkinson medication use…
- « Previous Page
- 1
- …
- 5
- 6
- 7